141 related articles for article (PubMed ID: 29511983)
1. Local Interleukin-2 Immunotherapy of Breast Cancer: Benefit and Risk in a Spontaneous Mouse Model.
Semushina SG; Aronov DA; Moiseeva EV
Pathol Oncol Res; 2019 Jul; 25(3):945-951. PubMed ID: 29511983
[TBL] [Abstract][Full Text] [Related]
2. [Criteria for the effectiveness of interleukin-2 immunotherapy in a spontaneous murine mammary tumor model].
Moiseeva EV; Semushina SG; Chaadaeva AV; Sadovnikova ES; Kessler IuV
Vopr Onkol; 2010; 56(4):443-9. PubMed ID: 20968024
[TBL] [Abstract][Full Text] [Related]
3. Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6.
Podnos A; Clark DA; Erin N; Yu K; Gorczynski RM
Breast Cancer Res Treat; 2012 Nov; 136(1):117-27. PubMed ID: 23053647
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model.
Mukherjee P; Tinder TL; Basu GD; Pathangey LB; Chen L; Gendler SJ
Breast Dis; 2004; 20():53-63. PubMed ID: 15687707
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-15 gene therapy and the mammalian target of rapamycin inhibitor everolimus inhibit the growth of metastatic breast cancer.
Zhao N; Li X; He X; Qiu Y; Zhu L; Qi F
J Gene Med; 2013 Oct; 15(10):366-74. PubMed ID: 24038990
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T Cells Control the Switch From
Martinez LM; Robila V; Clark NM; Du W; Idowu MO; Rutkowski MR; Bos PD
Front Immunol; 2019; 10():1942. PubMed ID: 31555258
[TBL] [Abstract][Full Text] [Related]
7. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
Saarloos MN; Khoo NK; Lala PK
Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
[TBL] [Abstract][Full Text] [Related]
8. Retrovirus-mediated IL-4 gene therapy in spontaneous adenocarcinomas from MMTV-neu transgenic mice.
Sacco M; Benedetti S; Catò EM; Caniatti M; Ceruti R; Scanziani E; Pirola B; Villa A; Finocchiaro G; Vezzoni P
Gene Ther; 1999 Nov; 6(11):1893-7. PubMed ID: 10602385
[TBL] [Abstract][Full Text] [Related]
9. Effects of IL-12 gene therapy on spontaneous transgenic and transplanted breast tumors.
Faggioli F; Soldati S; Scanziani E; Catò EM; Adorni F; Vezzoni P; Noonan DM; Sacco MG
Breast Cancer Res Treat; 2008 Jul; 110(2):223-6. PubMed ID: 17687642
[TBL] [Abstract][Full Text] [Related]
10. Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy.
Lala PK; Parhar RS
Int J Cancer; 1993 Jun; 54(4):677-84. PubMed ID: 8514459
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous canine mammary tumors. A model for monoclonal antibody diagnosis and treatment of human breast cancer.
Mottolese M; Morelli L; Agrimi U; Benevolo M; Sciarretta F; Antonucci G; Natali PG
Lab Invest; 1994 Aug; 71(2):182-7. PubMed ID: 8078297
[TBL] [Abstract][Full Text] [Related]
13. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts.
Tsai SC; Gansbacher B; Tait L; Miller FR; Heppner GH
J Natl Cancer Inst; 1993 Apr; 85(7):546-53. PubMed ID: 8455201
[TBL] [Abstract][Full Text] [Related]
14. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
15. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
16. Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody.
Rakhmilevich AL; Hooper AT; Hicklin DJ; Sondel PM
Mol Cancer Ther; 2004 Aug; 3(8):969-76. PubMed ID: 15299079
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of a single peritumoural dose of IL-2 on transplanted murine breast cancer.
Moiseeva EV; Merkulova IB; Bijleveld C; Koten JW; Miroshnikov AI; Den Otter W
Cancer Immunol Immunother; 2003 Aug; 52(8):487-96. PubMed ID: 12719897
[TBL] [Abstract][Full Text] [Related]
18. Combined immunotherapy of breast cancer with EGF and VEGF vaccines from DNA shuffling in a mouse model.
Jin D; Yu X; Chen B; Li Z; Ding J; Zhao X; Qi G
Immunotherapy; 2017 Jun; 9(7):537-553. PubMed ID: 28509606
[TBL] [Abstract][Full Text] [Related]
19. Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.
Dushyanthen S; Teo ZL; Caramia F; Savas P; Mintoff CP; Virassamy B; Henderson MA; Luen SJ; Mansour M; Kershaw MH; Trapani JA; Neeson PJ; Salgado R; McArthur GA; Balko JM; Beavis PA; Darcy PK; Loi S
Nat Commun; 2017 Sep; 8(1):606. PubMed ID: 28928458
[TBL] [Abstract][Full Text] [Related]
20. Effect of local interleukin-2 treatment on spontaneous tumours of different immunogenic strength.
Fiszer-Maliszewska L; Den Otter W; Mordarski M
Cancer Immunol Immunother; 1999 Feb; 47(6):307-14. PubMed ID: 10203060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
